Moreover, the 36-month beta value for DRMA is 0.45. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 1 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for DRMA is 3.99M and currently, short sellers hold a 4.73% of that float. On March 31, 2025, DRMA’s average trading volume was 1.61M shares.
DRMA) stock’s latest price update
The stock price of Dermata Therapeutics Inc (NASDAQ: DRMA) has dropped by -16.90 compared to previous close of 1.42. Despite this, the company has seen a fall of -4.84% in its stock price over the last five trading days. accessnewswire.com reported 2025-03-27 that SAN DIEGO, CA / ACCESS Newswire / March 27, 2025 / Dermata Therapeutics, Inc. (NASDAQ:DRMA)(NASDAQ:DRMAW) (“Dermata,” or the “Company”), a late-stage biotechnology company focused on the treatment of medical skin diseases and aesthetic applications, today announced the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase an aggregate of 4,834,470 shares of the Company’s common stock, having exercise prices of $1.58 and $4.91 per share, issued by Dermata in September 2024 (with respect to 3,825,138 warrants) and May 2024 (with respect to 1,009,332 warrants), at a reduced exercise price of $1.284 per share. The shares of common stock issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form S-3 (File Nos.
DRMA’s Market Performance
Dermata Therapeutics Inc (DRMA) has experienced a -4.84% fall in stock performance for the past week, with a 1.62% rise in the past month, and a -11.94% drop in the past quarter. The volatility ratio for the week is 22.91%, and the volatility levels for the past 30 days are at 10.60% for DRMA. The simple moving average for the past 20 days is -3.47% for DRMA’s stock, with a -25.66% simple moving average for the past 200 days.
DRMA Trading at -2.36% from the 50-Day Moving Average
After a stumble in the market that brought DRMA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -82.30% of loss for the given period.
Volatility was left at 10.60%, however, over the last 30 days, the volatility rate increased by 22.91%, as shares surge +3.51% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -15.11% lower at present.
During the last 5 trading sessions, DRMA fell by -4.84%, which changed the moving average for the period of 200-days by -61.69% in comparison to the 20-day moving average, which settled at $1.2225. In addition, Dermata Therapeutics Inc saw -12.59% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for DRMA
The total capital return value is set at -8.02. Equity return is now at value -310.44, with -213.46 for asset returns.
Currently, EBITDA for the company is -12.51 billion with net debt to EBITDA at 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.79.
Conclusion
To wrap up, the performance of Dermata Therapeutics Inc (DRMA) has been bad in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
